Summary
Introduction
Human immunoglobulin (Ig) accelerates recovery from
Material and methods
Guillain-Barré syndrome to the same extent as plasma Animals exchange (van der Meché et al., 1992 ; Plasma Exchange/ Male Lewis rats (200-250 g; Harlan, UK) were housed in Sandoglobulin Guillain-Barré Syndrome Trial Group, 1997) .
cages in pairs, and allowed free access to food (rat chow) However, why the administration of large amounts of normal and water. Ig from healthy donors should ameliorate the course of Guillain-Barré syndrome or indeed any of the other neurological or non-neurological inflammatory disorders is
Experimental protocol unknown. Human Ig is also effective in animal models
On day 0, all animals were immunized under halothane of human autoimmune disease, ameliorating experimental anaesthesia with 0.05 ml of an emulsion containing 0.25 mg autoimmune encephalomyelitis (EAE) and adjuvant arthritis Mycobacterium tuberculosis H37Ra and 2 mg dry weight of (Achiron et al., 1994) and preventing experimental autobovine myelin per rat in incomplete Freund's adjuvant, immune uveoretinitis (Saoudi et al., 1993) . We have tested into the right hind footpad. Three experiments were then the efficacy of human Ig in experimental autoimmune performed: in Experiment 1, animals were treated from neuritis (EAN) in order to investigate the mechanism of immunization, whereas in Experiments 2 and 3, treatment action of Ig in inflammatory neuropathy. EAN is an animal was from onset of signs of disease (with observation until model of Guillain-Barré syndrome in which similar inflam-21 days and 28 days from immunization, respectively). mation and demyelination in peripheral nerves occur as in acute inflammatory demyelinating polyradiculopathy. While our experiments were in progress others have reported
Experiment 1
conflicting results in EAN, namely successful inhibition of Twenty-four rats were immunized and randomly divided disease (Miyagi et al., 1995) on the one hand, and failure of treatment on the other (Enders et al., 1997) .
into three groups. Group 1 (n ϭ 8) received injections of shown. These were summed on each day to give the Daily Clinical Score (maximum score of 18). The interobserver variability of two blind assessors was low with an intraclass
Collection and processing of tissues correlation of 0.96 (Shrout and Fleiss, 1979) .
After the electromyographic recording, blood samples (2-5 ml) were taken from each animal by cardiac puncture 40 mg/100 g body weight intraperitoneal (i.p.) human Ig to obtain serum, which was stored at Ϫ70°C. In Experiment (Sandoglobulin, Sandoz, UK) once daily for 5 days com-2 the rats were then perfused under deep general anaesthesia mencing at the time of immunization. Group 2 (n ϭ 11) with glutaraldehyde (3% in 0.1 M phosphate buffer). The received once daily i.p. injections of human albumin (Human cauda equina and left sciatic nerve were removed and Albumin Solution 20%, Immuno, UK) at the same dose for processed into resin using a standard protocol for preparation 5 days. Group 3 (n ϭ 5) received the same volume (0.8 ml)
of 1 µm sections stained with thionin acetate and acridine of i.p. saline once daily for 5 days.
orange. Sections (70-80 nm) of cauda equina were stained with uranyl acetate and lead citrate for electron microscopic examination.
Experiment 2
Twenty rats were immunized and randomized into four groups, each of five animals. Group 1 received 40 mg/100 g
Serum analysis
body weight i.p. human Ig once daily for 5 days from the Rat or bovine peripheral myelin, as coating antigen for onset of neurological deficit. Group 2 received the same enzyme-linked immunoassay plates, was suspended at 50 µg dose of human Ig intravenously (i.v.). Group 3 received protein/ml in 0.3% methylglyoxal, prepared by diluting a the same dose of human albumin i.p., and Group 4 received stock 2% solution (pH 8) in water. Plates (Linbro, EIA II the same doses i.v.
Plus, Flow Laboratories) were coated with 50 µl aliquots and incubated for 2 h at 37°C. After washing once, 50 µl of rat serum (diluted 1/250 in 1% bovine serum albumin-
Experiment 3
phosphate-buffered saline) was added to each well and the Twenty rats were immunized and at the time of onset of plates were kept at 10°C overnight. All sera were tested in signs of disease they were divided into two groups matched for triplicate. After washing, 50 µl of 1/1000 anti-rat alkaline weight and clinical score. Group 1 (n ϭ 10) received 40 mg/ phosphatase IgG conjugate (Sigma) was added and incubated 100 g body weight i.p. human Ig; Group 2 (n ϭ 10) received for 2 h. The plates were washed, developed with p-nitrophenol the same dose of human albumin. All treatments were given phosphate and read at 405 nm. without anaesthesia.
Histological analysis Monitoring of animals
Rats were weighed and examined daily for signs of disease
Light microscope examination
The severity of histological change in the tissues sampled was by an observer blind to the therapy received. The severity of EAN was scored according to our own scale (Table 1) . graded 0, 1, 2 or 3 for the presence of each of oedema, cellular infiltration by an observer blinded to treatment (0 ϭ normal; 1 ϭ mild, Ͻ10% fibres affected; 2 ϭ moderate, 10-50% fibres affected; 3 ϭ severe, Ͼ50% fibres affected). calculated using the Mann-Whitney U-test using twotailed significance tests.
Electron microscope examination
Following the observation of a greater proportion of Results remyelinated axons in the Ig-treated group in Experiment 2,
Weights and clinical scores
more detailed electron microscope examination was undertaken on the material available. Randomly selected
Experiment 1: treatment from immunization
roots of all intraperitoneally treated animals from Experiment The rats given human Ig or albumin for 5 days from the 2 were viewed at a magnification of ϫ600 and photographs time of immunization developed slightly, but not signiof eight fields were taken (total area 0.13 mm 2 /animal) The ficantly, less severe EAN than those given saline. The animals total number of axons, the number demyelinated and the given Ig recovered slightly faster than those given albumin number remyelinated were counted in each field by an (P ϭ 0.1 on day 20) (Fig. 1) . observer blinded to treatment.
Experiments 2 and 3: treatment from disease Statistical analysis
The primary outcome criterion was the difference in the onset Treatment with i.v. human Ig did not prevent loss of weight, severity of clinical disease (the sum of the clinical score on each day) between each group. Secondary outcome criteria but resulted in more rapid recovery from clinical disease (P ϭ 0.02 on day 21) (Fig. 2) . Treatment with i.p. human were the differences in weights, proximal and distal CMAP amplitudes, NCV and cumulative histological score of Ig resulted in less weight loss than in controls (P Ͻ 0.05) ( Figs 3A and 4A ). The disease severity of the groups given sections. Differences between clinical scores and weights of each treatment group on each day and between i.p. human Ig was less than the corresponding groups given albumin (P Ͻ 0.05 from day 17 to day 23) (Figs 3B and 4B). neurophysiological and histological parameters were There were no significant differences in CMAP amplitude or NCV between groups in any individual experiments, although there was a trend towards larger CMAP amplitude and faster NCV in the human Ig-treated groups when measured on day 21. On day 28, when there was no difference in clinical disease severity, there were no differences in CMAP amplitude (Fig. 5) or NCV between Ig and albumin groups.
Histology
The caudae equinae of both Ig-and albumin-treated animals showed multifocal oedema, cellular infiltration, demyelination, remyelination and axonal degeneration, with considerable variation in severity between different roots in the same animal. There were no significant differences in the extent of these changes between the groups (Table 2) , but the proportion of remyelinated compared with demyelinated nerve fibres appeared more prominent in the Ig-treated animals (Fig. 6) . The predominant change in the sciatic nerves was extensive axonal degeneration, which varied in degree and sometimes affected almost all the nerve fibres but was not significantly more in one group than the other. Our preliminary observation of enhanced remyelination in animals treated with human Ig was supported by electron microscope morphometric examination, which confirmed a The mean (SD) percentage of remyelinated fibres, expressed days of treatment, *days in which the difference was significant at P Ͻ 0.05). Animals observed for 28 days from immunization.
as a percentage of the total demyelinated and remyelinated i.p. human Ig 5 3 (2-3) 2 -3) 3 (1-3) 2 (1-2.5) 0 (0-1) 1.5 (0.5-2.5) 3 (2-3) 1.5 (0-2) 0 (0) 3 (1-3) i.p. albumin 5 3 (2-3) 2 (1-3) 3 (1-3) 2 (1-2) 0 (0-1) 1.5 (1-3) 3 (0-3) 1 (0-2) 0 (0) 1 (0-2)
Scores are given as median (range).
fibres in the Ig-treated group, was 43 (35) compared with 21
Intraperitoneal versus intravenous treatments
(24) in the albumin-treated group (P ϭ 0.06). The greater observed effect with i.p. compared with i.v. treatment may be due either to masking of any difference in the early stages between the Ig and control groups by a stress response induced by the i.v. injection, to detrimental effects Serology of an i.v. bolus of allogeneic protein, or to a beneficial The amount of anti-rat myelin antibody was significantly less effect of slower absorption of Ig via the peritoneal route. (P Ͻ 0.05) when measured on day 21 in the human IgAlternatively, i.p. treatment may confer some immunological treated group compared with the human albumin-treated advantage, potentially increasing the distribution of Ig to group. There was no difference between the groups when lymph nodes via diaphragmatic, paravertebral and parasternal titres were measured on day 28 (Fig. 7) .
lymph vessels (Olin and Saldeen, 1964; Langhammer et al., 1973; Parker et al., 1981) .
Discussion
Our results indicate that the administration of intraperitoneal
Timing of treatment
Ig at the time of onset of signs of disease significantly Treatment from disease onset was more beneficial than accelerates recovery from EAN. Previous investigation into treatment from immunization. This suggests an effect on the the effect of human Ig on EAN has produced conflicting late inflammatory phases of the disease rather than the initial results. Miyagi et al. (1995) found that in Lewis rats with immunization process, which holds out promise for Ig as a EAN induced by synthetic peptide from bovine P 2 protein therapy in established inflammatory neuropathy. Lymph nodes (SP26), intravenous treatment with human Ig (Venilon, Teijin) of rats with EAN contain elevated numbers of B cells secreting prevented paralysis, but only if given at the time of immunizaIgM anti-myelin antibodies by 7 days after immunization, and tion or before the onset of clinical signs. In contrast, Enders maximum IgG responses at the height of clinical disease et al. (1997) found that intravenously applied human Ig (Zhu et al., 1994) . If the response of EAN to Ig is primarily (Sandoglobulin, Sandoz, UK) did not prevent the development via an anti-idiotype mechanism, as described below, then it of EAN induced either by active immunization or adoptive may have its greatest effect when given at the time of transfer of T cell lines directed against P2. Their experiments maximal autoantibody production. The half-life of human Ig in active EAN were terminated on day 16, a time when in rats is probably shorter than in humans, which would we also did not show a significant difference between accentuate the effect of changing time of treatment, and intravenously and intraperitoneally administered Ig. In their could result in serum levels that are subtherapeutic by the experiments detailed histological analysis on day 16 did not time of autoantibody production and disease onset if given show a significant difference in T cell and macrophage from the time of immunization. infiltration between Ig recipients and control animals. Thus
In our experiments, the clinical benefit from Ig lasted for our experiments are complementary, demonstrating that up to 15 days. The improvement of the CMAP suggested on human Ig increases the rate of recovery but does not prevent day 21 was not present on day 28. The loss of effect could development or progression of disease. Neither of these be due either to a reduction in half-life of human Ig in rats results is directly comparable with our own as there are or to a limit to any treatment effect with the dose given. On methodological differences between each of the studies.
the other hand, it may be that the maximum effect of Ig had We used a novel grading scale which has good inter-rater occurred by day 21 and following this no further improvement reproducibility (Table 1) and is more sensitive at detecting was possible. small changes in clinical disease than our previous scale (Watts et al., 1989) . Although we did not find significant changes between the groups in the electrophysiology and light microscope measures, we consider that clinical changes
Histological findings
No difference in the severity of histological scores was noted are a more accurate integrative measure of the burden of disease throughout the peripheral nervous system. on day 21. The histological sampling may have been too effectiveness depends upon more specific anti-idiotypic properties or the mass action suppression of inflammation is unclear. Involvement of anti-idiotype activity may explain why not all patients respond to Ig, although it appears to be effective in a wide variety of autoimmune diseases.
Convincing evidence for anti-idiotypic activity of Ig against autoantibodies comes from the observation of a reduction in antihaemophilic factor (anti-factor VIII:C) antibodies in patients with anti-factor VIII:C autoimmune disease treated with F(ab) 2 fragments of Ig (Sultan et al., 1987) . Autoantibodies also bind to affinity columns of whole Ig (Ronda et al., 1994) or F(ab) 2 fragments (Rossi and Kazatchkine, 1989) . Autoantibodies against neuroblastoma cells in the serum of patients with Guillain-Barré syndrome were inhibited by F(ab) 2 fragments in the serum of the same (Experiments 1 and 2) and day 28 (Experiment 3) in groups treated with i.p. human Ig (Ig), human albumin (Alb) and saline patient following recovery (van Doorn et al., 1990) , indicating (Sal) . There were significant differences between the Ig-and that anti-idiotypic effects may also be important in the natural albumin-treated groups in both experiments at day 21, but not on recovery from this condition.
day 28.
In addition to interactions with antibody, variable regions of Ig may interact with T cell receptors (Marchalonis et al., limited to detect a global difference in disease as sensitively 1992) or other T cell surface molecules, including CD5 as the clinical scoring system. Alternatively, it may be that (Vassilev et al., 1993) and CD4 (Hurez et al., 1994) . changes that are occurring to produce functional improvePrevention of experimental autoimmune uveoretinitis by Ig ments are not seen at the histological level (such as changes (Saoudi et al., 1993) was associated with decreased in membrane channels). We observed that the proportion of lymphocyte proliferative and secretory responses to the demyelinated fibres which had started to remyelinate was stimulating antigen compatible with induction of T cell greater in the Ig-treated animals. Administration of Ig is anergy. known to enhance CNS remyelination in Theiler's virus
In both EAE and adjuvant arthritis, Ig inhibits the encephalomyelitis in mice (Rodriguez and Lennon, 1990;  production of the pro-inflammatory cytokine, TNF-α van Engelen et al., 1994) . These authors have proposed (Achiron et al., 1994) , measured by cell toxicity assay, which that a component of Ig treatment directly stimulates the could be via interaction with Th1 cells or with macrophages. remyelination of demyelinated axons. However, the easiest Finally, Ig induces transcription and secretion of IL-1 receptor explanation of this action of Ig would be by enhanced antagonist and IL-8 in human monocyte cultures (Ruiz de downregulation of the immune response, reducing the total Souza et al., 1995) , which could contribute to the antiamount of demyelination or permitting earlier recovery. inflammatory effect. Blockade of Fc receptors on macrophages has been shown in the treatment of idiopathic thrombocytopenic purpura since clearance of anti-Rh(D) sensitized erythrocytes is delayed by
Effect of Ig on immune response
The serum of animals with EAN contains factors which Ig (Fehr et al., 1982) . Binding of IgG to Fc receptors in vitro induce complement-dependent demyelination both in mouse induces production of soluble Fc receptors (Lowy et al., dorsal root ganglion cultures (Raine and Bornstein, 1979) 1983), which can neutralize autoantibodies and down-regulate and following intraneural injection into the rat sciatic nerve local immunoglobulin production. Similar mechanisms could (Saida et al., 1978) . Co-administration of antimyelin serum be involved in peripheral nerve disease since Fc receptors with a T cell line directed against P2 increases the severity are found on Schwann cells, perineurial and endothelial of disease and the amount of demyelination (Hahn et al., cells, and endoneurial macrophages (Vedeler, 1987) . Also, 1993). In our experiments the amount of anti-rat nerve Ig prevents the deposition of C3 and C4 fragments onto antibody was suppressed on day 21, at the time when the antibody-sensitized erythrocytes (Basta et al., 1991) and clinical severity was reduced by human Ig, but not on day could modulate acute, complement-mediated damage. 28, when the protective effect was no longer so evident Our demonstration of a therapeutic effect of Ig on EAN (Fig. 7 ).
provides a model by which the therapeutic mechanism of Ig in inflammatory demyelinating polyneuropathy may be explored.
Possible modes of action of Ig
The therapeutic effects of Ig in EAN and other autoimmune diseases are considered to reflect a general regulatory action
